LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC)(IMUC), a biotechnology company, presented data showing an immunological response against cancer stem cells (CSCs) derived from brain cancer, specifically glioblastoma. It has been demonstrated in the last few years that CD-133, a cell surface marker, is present on many different types of cancer stem cells and should therefore make an excellent target for ICT-121, the company’s cancer stem cell vaccine product candidate, which is specifically designed to generate a T cell response against CD-133.
